



Patents Issue for Inotek Pharmaceuticals' Lead Clinical Candidates in Glaucoma and Contrast-Induced Nephropathy

BEVERLY, Mass., November 13, 2008

Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company's two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Patent number 7,432,369 relates to INO-4885, in clinical development for the prevention of contrast-induced nephropathy.

"These patents cover important technology discovered and developed by Inotek scientists and serve as an initial foundation for our growing pipeline in ophthalmology and other select indications with significant unmet medical need," said Paul G. Howes, President & Chief Executive Officer of Inotek.

INO-8875 is a selective adenosine 1 agonist in Phase 1 clinical development as a topical agent for the treatment of elevated intraocular pressure associated with primary open angle glaucoma and ocular hypertension. Adenosine 1 receptors have been shown to play a role in reducing intraocular pressure by increasing the outflow of ocular fluid via the trabecular meshwork pathway.

INO-4885 is a peroxydinitrite decomposition catalyst in Phase 1 clinical development for the prevention of contrast-induced nephropathy in patients undergoing procedures involving contrast imaging agents who are at high risk of kidney damage. This indication represents a large market with high unmet needs for which there are currently no approved therapies.

About Inotek Pharmaceuticals

Inotek is a clinical-stage, drug-development company located in Massachusetts with two clinical-stage programs being developed for glaucoma and contrast-induced nephropathy. The Company's preclinical programs include products in development for various other ophthalmology indications which target mechanisms believed to play a role in ocular disease progression. Inotek also has preclinical programs targeting PARP and flagellin with applications in cancer and inflammatory bowel disease.

Contacts:

Sarah Cavanaugh
MacDougall Biomedical Communications
(781) 235-3060